Upfront Briefing
Monday opens with a long-awaited launch, a longer-acting bet and an early approval. AbbVie finally has a sellable drug from its $8.7B Cerevel buy after FDA cleared Parkinson's pill Juvmo; Novo licensed Nanexa's depot-coating tech in a €1.165B pact aimed at monthly and quarterly obesity shots; and Merck's Welireg-Lenvima doublet beat its PDUFA date by ten days in post-IO kidney cancer.
EASD opens in Milan today and runs the week's obesity scoreboard: Novo's CagriSema REIMAGINE 1 data, then Lilly's retatrutide TRIUMPH-2 and Mounjaro SURPASS-CVOT symposia on Wednesday. Bring a spreadsheet and a strong espresso.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,743.4 |
+0.5% |
+12.9% |
| Nasdaq 100 |
30,608.1 |
+0.4% |
+21.4% |
| Russell 2000 |
2,837.6 |
+0.1% |
+13.1% |
| Healthcare (XLV) |
170.7 |
+0.5% |
+9.8% |
| Biotech (XBI) |
155.0 |
(0.7%) |
+27.6% |
| Nasdaq Biotech (NBI) |
7,084.4 |
+0.1% |
+24.1% |
| Clinical Trials (BBC) |
45.1 |
(1.4%) |
+20.0% |
|
- Biotech lagged a green tape with no single sector catalyst: equal-weight XBI (0.7%) and clinical-stage BBC (1.4%) trailed cap-weighted NBI +0.1% and XLV +0.5%, a large-cap-over-beta split that has held since Wednesday's rate-driven 4.1% XBI drop.
- Stocks rose even as the 10-year Treasury yield touched 5.18%, its highest since the financial crisis: WTI fell 2.3% to $92.41 after Iran offered to reopen the Strait of Hormuz within seven days, lifting the S&P 500 +0.5% and the Dow +0.9% to weekly gains, while University of Michigan sentiment slid to a four-month low.
- Market data: U.S. cash close Friday, 25 September 2026.
The Big 3
|
1
|
FDA approves AbbVie's Juvmo, the payoff pill from its $8.7B Cerevel buy
|
- The FDA approved Juvmo (tavapadon), a once-daily D1/D5 partial dopamine agonist from AbbVie's Cerevel buyout, for adults with Parkinson's disease on Friday. The approval rests on the three-trial Phase 3 TEMPO program: monotherapy improved MDS-UPDRS Parts II+III versus placebo in early disease, and as a levodopa add-on it delivered about 1.1 extra hours of "on" time without troublesome dyskinesia.
- Why it matters: Juvmo is now the main asset carrying AbbVie's $8.7B Cerevel acquisition, after emraclidine failed both EMPOWER schizophrenia trials in late 2024. The pitch is selectivity: pramipexole and ropinirole hit D2/D3 receptors and bring somnolence, hallucinations and impulse-control problems, while tavapadon partially activates D1/D5 on the direct motor pathway. The comparator set is the problem. Those agonists are cheap generics, roughly an extra hour of "on" time in TEMPO-3 is incremental, and AbbVie already sells Vyalev for advanced disease. Citi had modelled a gradual ramp while Medicare coverage is negotiated, and AbbVie has not yet disclosed launch timing or price. Payer access will set the curve more than the label.
- Source: Endpoints
- More: Reuters
|
|
2
|
Novo licenses Nanexa's depot tech in €1.165B push for monthly obesity shots
|
- Novo took an exclusive global licence to Nanexa's PharmaShell long-acting injectable platform for up to five peptide programs in obesity, type 2 diabetes and other cardiometabolic diseases, targeting monthly and quarterly dosing. The €1.165B ($1.33B) headline splits into up to €615M ($700M) of upfront plus development and regulatory milestones and €550M ($626M) of sales milestones; the upfront is undisclosed.
- Why it matters: Novo is buying formulation rather than new molecules: PharmaShell coats drug particles in an inorganic shell that dissolves slowly from a depot, giving Novo up to five attempts at turning existing peptides into monthly or quarterly products. Only €615M of the €1.165B headline is pre-commercial. The nearest comp on the undisclosed upfront is Moderna's $3M entry fee last year for a Nanexa platform pact billed at up to $500M. The rationale is Novo's own: at last week's Capital Markets Day, CSO Martin Holst Lange said native half-lives do not lend themselves to monthly dosing and questioned the tolerability of Pfizer's monthly Metsera GLP-1. Lilly struck an $870M deal for Camurus' depot technology last year. Depot release now has to hold GI tolerability at monthly peaks.
- Source: Fierce Biotech
- More: Nanexa
|
| 3 |
Merck's Welireg-Lenvima doublet lands post-IO kidney cancer nod, 10 days early
|
- FDA approved Welireg (belzutifan) plus Eisai's Lenvima (lenvatinib) on 24 September for advanced clear-cell RCC after a PD-1/PD-L1 inhibitor, ten days before the 4 October PDUFA date. In LITESPARK-011 (n=747), the all-oral doublet cut the risk of progression or death by 26% versus cabozantinib (HR 0.74; median PFS 14.6 vs 10.6 months) and lifted ORR to 53% from 40%.
- Why it matters: LITESPARK-011 is the first Phase 3 in post-IO kidney cancer run against an active TKI, and the comparator is Exelixis' Cabometyx, the incumbent second-line standard. The catch sits in the dual primary endpoint: overall survival missed significance at the final analysis, so the label rests on a four-month PFS gain, with full data due at ESMO in Madrid next month. Welireg already held a later-line RCC monotherapy label; the doublet moves it one line earlier, and Eisai adds a second-line use for Lenvima behind its first-line Keytruda pairing. Cabometyx keeps a tolerability argument: the doublet stacks VEGF-TKI toxicity on belzutifan's anaemia, hypoxia and boxed embryo-fetal warning, without an OS claim to offset it.
- Source: Fierce Pharma
- More: FDA
|
Everything Else that broke
- FDA approved Mirum's once-daily ALK2 inhibitor Atebrioz (zilurgisertib), licensed from Incyte for $16M upfront in April, for fibrodysplasia ossificans progressiva in patients 12 and up, the third FOP drug after Ipsen's Sohonos and Regeneron's Pasatru. — Fierce Pharma
- Five years after a single Carvykti infusion, 10 of 20 patients in CARTITUDE-2 Cohort A (one to three prior lines) remained alive and progression-free without further treatment, with five-year OS of 69.2%, per IMS data. — BioSpace
- A federal jury found Lilly breached the implied covenant of good faith in the terminated rezpeg partnership and awarded Nektar $90M plus interest, a tenth of the $1B it sought; NKTR finished Friday flat. — BioSpace
- Drugmakers asked FDA for clearer standards on when one pivotal trial is enough. — Endpoints
- IASO Bio's BCMA-targeted in vivo CAR-T IASO206 posted 90% ORR (9/10) and 90% MRD negativity in its first-in-human IMS late-breaker, with no apheresis or lymphodepletion; both rates hit 100% at the high dose. — PR Newswire
- Lepu Medical sued BD consultant Su Zhang, credited with pioneering the China NewCo model, alleging she secretly served as acting CBO of rival BrightGene while shopping Lepu's GLP-1 assets; the case is now in federal court in New York. — Fierce Biotech
- Indivior handed Addex back its GABAB PAM portfolio ahead of its merger with Supernus, ending the collaboration. — Fierce Biotech
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Novo licensed Nanexa's PharmaShell long-acting injectable platform for up to five cardiometabolic peptide programs in a €1.165B ($1.33B) pact, €550M of it sales milestones (see The Big 3). — Fierce Biotech
- Genentech will pay Earendil Labs $55M upfront, with milestones taking the value above $1.5B, for oncology bispecifics against pre-agreed target pairs; Earendil runs discovery through early clinic. — Fierce Biotech
VC / Private Financings
- No notable VC / private financings since Friday's edition.
IPOs / Follow-Ons
- ADARx (ADRX) opened 30% above its $17 IPO price at $22.10 in Friday's Nasdaq debut and closed at $19.35 (+13.8%); the $446.3M offering closes today. — Bloomberg
|
